Steve Liapis, Ph.D.

Steve Liapis is a Director at Northpond Ventures where he focuses on biotechnology platforms and therapeutics and leads Northpond’s newco incubation efforts with the Wyss Institute at Harvard and the School of Engineering at MIT. Steve is Board Director at Kyverna Therapeutics, Opna Bio, Parthenon Therapeutics, and Totus Medicines, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology. Prior to Sanofi, Steve was Head of Strategy at Arbor Biotechnologies and served in leadership positions at L.E.K. Consulting where he focused on R&D and commercial strategy for immuno-oncology as well as advanced therapeutic modalities including gene therapy, gene editing, and cell therapy. Steve holds a Ph.D. in molecular biology from Harvard University where he trained in the laboratory of Dr. John Rinn, focusing on the discovery and molecular characterization of novel long noncoding RNAs (lncRNAs), as well as identifying the role of lncRNAs in disease pathogenesis. He also holds a Master’s Degree in Genetics and Plant Biology from Yale University and an undergraduate degree in environmental science from Stockton College.